Nvidia Corp.’s blowout sales forecast took center stage in markets, fanning gains in tech stocks around the world and propelling Nasdaq 100 futures to a 2%…
By the first quarter 2022, 57% of US adults with type 2 diabetes taking an incretin-based agent were taking a GLP-1 receptor agonist; DPP-4 inhibitor use fell to 39% of these scripts.